Sector News

AstraZeneca divests gastrointestinal drug for $215 million

July 9, 2015
Life sciences
AstraZeneca struck a further “externalization” deal on Thursday to help fill its short-term revenue gap by divesting its gastrointestinal drug Entocort for $215 million.
 
The British drugmaker, which has high hopes for its new drug pipeline but faces declining sales as older products lose patent protection, said rights to Entocort outside the United States would be acquired by Tillotts Pharma, part of the Zeria Group.
 
Entocort, or budesonide, is used to treat patients with mild to moderate Crohn’s disease and ulcerative colitis. It is sold in more than 40 countries and had sales of $53 million outside the United States in 2014.
 
The transaction is expected to complete in the second half of 2015 and AstraZeneca said it would reinforce its strategic focus on selected therapy areas, such as cancer, respiratory disease and diabetes.
 
Chief Executive Pascal Soriot argues that spinning off non-core businesses like Entocort will help the company’s finances and allow it to invest for the future, but some analysts are worried about its reliance on such deals.
 
The issue came to a head in April when AstraZeneca said it was getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers.
 
Soriot has also struck cash-generating externalization deals with Eli Lilly in Alzheimer’s and with Daiichi Sankyo for a new constipation drug.
 
(Reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend